Biogen announces plans to start their global phase 3 trial of Omaveloxolone in children aged 2-15, with sites in the UK - Ataxia UK

Biogen announces plans to start their global phase 3 trial of Omaveloxolone in children aged 2-15, with sites in the UK

Post Published: May 7, 2025

Biogen have shared their plan to initiate their BRAVE study, a global phase 3 trial of Omaveloxolone (SKYCLARYS®) in children aged 2-15 years. The trial will study the effects and long-term safety of the drug in this population. 

The London Ataxia Centre, Sheffield Ataxia Centre and Oxford Ataxia Centre are UK sites for this trial. Individuals interested in taking part should speak to their healthcare provider.

Read Biogen’s letter to FA community here.

Read more about the trial here.

Read more about Omaveloxolone here.

RECENT POSTS

Living with Late Onset – Exercise and FA

Read More →

Virtual Activities

Read More →

Reflections from the International Drug Repurposing Conference 2025

Read More →

Subscribe To Our Newsletter

fundraise image

FUNDRAISE FOR US

Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Click to find out more
Donate Image

DONATE

To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Click Here
Volunteer Image

VOLUNTEER WITH US

Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Click to find out more
Cart
Checkout - £0.00
  • 0
  • 1
Scroll to Top